Endothelial dysfunction often precedes the development of cardiovascular diseases,
including heart failure. The cardioprotective benefits of sodium-glucose cotransporter 2 …

An increasing number of individuals are at high risk of type 2 diabetes (T2D) and its
cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD) …

Background The effect of empagliflozin, a sodium-glucose-co-transporter-2 inhibitor, on risk
for myocardial infarction has not been fully characterized. Methods This study comprised …

Heart failure with preserved ejection fraction (HFpEF) represents an entity with complex
pathophysiologic pathways, among which coronary microvascular dysfunction (CMD) is …

Different multifactorial pathophysiological processes are involved in the development of
heart failure (HF), including neurohormonal dysfunction, the hypertrophy of cardiomyocytes …

Lately, a large number of stable ischemic patients, with no obstructed coronary arteries are
being diagnosed. Despite this condition, which is being described as angina with no …

The balance between bleeding and cardiovascular events by dual antiplatelet treatment
(DAPT) is a critical concern in patients undergoing percutaneous coronary intervention …

Heart failure and cognitive impairment emerge as public health problems that need to be
addressed due to the aging global population. The conditions that often coexist are strongly …

Peripheral artery disease (PAD) shares common clinical risk factors, for example,
endothelial dysfunction, with preserved ejection fraction (LVEF) heart failure (HFpEF) …

While essential hypertension (HTN) is very prevalent, pulmonary arterial hypertension (PAH)
is very rare in the general population. However, due to progressive heart failure, prognoses …